Full text is available at the source.
GLP-1R agonists for the treatment of obesity: a patent review (2015-present)
GLP-1 receptor drugs for treating obesity: review of recent patents (2015-present)
AI simplified
Abstract
Liraglutide accounts for approximately 56% of the global obesity drug market.
- Modified GLP-1 receptor agonists may exhibit significant anti-obesity effects.
- Long-acting analogues and multifunctional peptides are associated with good weight loss activity.
- Recent patents detail various forms of GLP-1 receptor agonists, including small molecules and recombinant fusion proteins.
- Clinical trials of GLP-1 receptor agonists are increasing, indicating a growing interest in their use for obesity treatment.
AI simplified